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: Renal failure continues to carry substantial burden of morbidity
and mortality in both acute and chronic forms, despite advances in transplan-
tation and dialysis. There is evidence to suggest that the kidney has metabolic,
endocrine, and immune effects transcending its filtration functions, even
beyond secretion of renin and erythropoietin. Our laboratory has developed
experience in the tissue culture of renal parenchymal cells, and has now been
able to demonstrate the metabolic activity of these cells in an extracorporeal
circuit recapitulating glomerulotubular anatomy. We have observed active
transport of sodium, glucose, and glutathione. We describe the design and ini-
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SCOPE OF THE PROBLEM OF RENAL FAILURE
 





 substitutive therapy has been available. Kolff’s first hemodialyzer
was successfully applied to a human patient with acute renal failure in 1948, and the
first successful allograft transplantation was a kidney by David Humes, John Merrill,
and Joseph Murray in 1951, for which a Nobel prize was awarded. Both treatments
are used today. The annual mortality for patients between 40 and 60 years of age with




, whereas that for age-








 The statistics for
acute renal failure are similarly grim, with overall survival unmoved from its pre-








 Acute renal failure as a component of
multiorgan dysfunction syndrome (MODS) carries an especially poor prognosis,








 The problem is likely to continue to grow in mag-
nitude, since the population of patients with end-stage renal disease (ESRD) in the




 per year, although the number of








The reasons for the markedly improved prognosis of patients transplanted with
allograft kidneys cannot be explained solely by the better health of patients listed for
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 We deduce that the intact or transplanted kidney provides
function to the host that intermittent hemodialysis does not.
Hemodialysis provides clearance of small molecules in blood by diffusive flow
across a semipermeable membrane, and control of volume status by bulk flow of
water and solutes through that membrane. These short-term effects are sufficient
to abrogate the lethal acidosis, volume overload, and uremic syndromes that accom-
pany renal failure, but do not protect the patient from the increased mortality asso-
ciated with dialysis-treated renal failure in either the acute or chronic form. Thus, the
metabolic, endocrine, and immune roles of the functioning kidney are candidate
mechanisms for the difference in survival noted above. The dialytic clearance of glu-
tathione, a key tripeptide in free radical scavenging and protection against oxidant
stress, the negative nitrogen balance and energy loss in the clearance of peptides and
amino acids in dialysate, loss of oxidative deamination and gluconeogenesis in the
tubule cell, and loss of cytokine and hormone metabolic activity by the kidney each
impose substantial stress upon the dialyzed patient, and as such are appropriate tar-
gets for improved renal replacement therapy.
 
RENAL CELLS AND RENAL ROLES
 
The kidney’s functional unit, the nephron, provides for the elimination of wastes
and toxins without the need for specific enzymes and transporters for each toxin. All
but the large proteins and cellular elements in the blood are filtered; a system of cells
reclaims specific filtered substances needed by the body, and allows all others to pass
as urine. Teleologically, this allows each organism to cope with novel insults its
genetic forebears may not have encountered.
Filtration is accomplished by the glomerulus, a tuft of capillaries supported by a
basement membrane and specialized epithelial cells called podocytes. The renal
proximal tubule, a hollow tube of cells surrounded by capillaries, receives the filtrate
from the glomerulus and accomplishes the bulk of reclamation of salt, water, glu-
cose, small proteins, amino acids, glutathione, and other substances. The tubule also
accomplishes metabolic functions including excretion of acid as ammonia, hydrox-





Intermittent hemodialysis is thought to replace the filtration function of the glom-
erulus. Our attention is drawn to duplicating the function of the proximal tubule. The
transport of solutes and water is accomplished by ATP-driven electrolyte transport-
ers in the luminal cell membrane. Reabsorption of small proteins and peptides in the
filtrate stream is accomplished by membrane-bound proteases and specific amino
acid transport proteins within the luminal membrane of the tubule cell. These amino
acids are either used for protein and peptide synthesis in the tubule cell, or are trans-
ported into the capillaries for transport to and use by the body. The diversity and
specificity of the functions of the proximal tubule cell argue against the development
of an electromechanical or polymeric substitute, and thus, a number of years ago, our
research group turned its attention to the isolation and culture of renal proximal
tubule cells. That research has culminated in the hollow-fiber bioreactor discussed
below.
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DESIGN AND IMPLEMENTATION OF A 
HOLLOW-FIBER BIOREACTOR
 
Selection of Proximal Tubule Cells
 
Implementation and eventual manufacture of a device based on cell therapy
requires a steady and predictable supply of tissues from which cells may be isolated
and cultured. Until such time as stem cells may be isolated and induced to differentiate
into organ-specific cell types, cells for allotransplantation, xenotransplantation, or bio-
artificial organ use will need to be procured through the harvest of animal or human
tissues.
 
Human kidneys unsuitable for cadaveric transplant have been used as a source of
proximal tubule cells in our laboratory, but the potential for infectious complications
looms large and mandates extensive screening and testing of each donor and each
harvested kidney. There is also a limited supply of these organs since they represent
a side-stream of the limited supply of organs for available for transplant. Similarly,
some of the characteristics rendering them unsuitable for transplantation may
adversely affect the harvest of cells from the kidneys.
There has been extensive research in xenotransplantation and bioengineering









 have achieved a degree of comfort with porcine cells. Pigs are com-
mercially bred and available in large number, and have similar organ sizes to
humans. There is considerable concern about the potential for zoonotic spread of
viruses, particularly after the demonstration that porcine endogenous retroviruses




Although most preclinical studies have used porcine cells in preparation of clin-
ical trials, the FDA encouraged us to carry out experiments using human cells in our
bioartificial kidney to continue progress in this field. Accordingly, biocomparability
studies, including metabolic, transport, and endocrine functionality have been com-
pleted between porcine and human proximal tubule cells. Human cells were obtained
both from postmortem specimens as well as transplant discards. Human proximal
tubule cells (HPTC) have recently been characterized in order to compare function-
ality between the two tissue sources. Metabolic assessment included ammonia and













 cells/24 hours. Ammonia production rates were pH responsive in





cells/hour, respectively. Glutathione metabolism was inhibited in
both cell types by the addition of acivicin, a specific inhibitor of glutathione metab-
olism. The reabsorptive function was evaluated with glucose transport. PPTC and













cose transport in both cell types was inhibited by the addition of phlorizin, a specific







 production. With the addition of parathyroid hormone, PPTC
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 cells/24 hours, for PPTC and HPTC respectively, when
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are biocomparable with respect to transport, metabolic, and endocrine functions in
cell culture.
 
Isolation and Culture of Proximal Tubule Cells
 
Our laboratory developed experience in the isolation and culture of porcine prox-





In brief, Yorkshire breed pigs were sacrificed at four to six weeks of
age and their kidneys harvested. The renal cortices were dissected, minced, digested
with collagenase, and the resulting mixture was separated on a Percoll density
gradient. Renal proximal tubule fragments were isolated and grown in a serum-free,
hormonally derived medium. After third passage and reaching confluence on
100-mm culture dishes, cells were mobilized with trypsin into a suspension and
seeded into polysulfone single hollow-fiber bioreactors (Fresenius AG BadHam-





of cell viability and metabolic activity.
 
Characterization of a Single Hollow-Fiber Bioreactor
 
Cellular attachment, stability, and confluence on the interior lumen of the biore-
actor is of paramount importance. To promote attachment of the cells, the luminal
surface of the polysulfone membrane was coated with ProNectin-L (Protein Poly-
mer, San Diego, CA, USA). ProNectin-L is a synthetic protein sharing the intercel-





 Laminin and collagen type IV, key components of the
tubular basement membrane, also provide an effective biomatrix for cell attachment
and growth. After seeding of the hollow fiber with tubule cells, the hollow fibers
were perfused with culture media. Because newly seeded cells need time to attach,
perfusion was initially performed via diffusion from the exterior through the
polysulfone membrane, and after time for attachment, convective flow through the
interior of the fiber was initiated. A graduated increase in flow (and, thus, shear forc-
es) was used to condition the cells and minimize cellular detachment. Studies dem-
onstrated that confluence was reached in seven to ten days. After fourteen days in
culture the hollow fiber bioreactors were assessed for cellular confluency and viabil-
ity. Light microscopy of fixed sections showed evidence of a confluent monolayer









-labelled inulin, a compound freely filtered by the glomerulus and by
dialysis membranes, but not absorbed nor secreted by the tubule, was perfused
through the lumen of the bioreactor. The amount of radioactivity in the luminal fluid
and in the extraluminal fluid were compared, to verify minimal insulin transport




Transport and Metabolic Characteristics of Hollow-Fiber Bioreactors
 
Because initial experiments using the single hollow-fiber model were promising,
the design was scaled up to use commercially available polysulfone hollow fiber
dialysis cartridges from the manufacturers of the single hollow fibers. Single hollow-
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 surface area cartridges.
Vectorial transport of sodium and water across the monolayers was assessed by
perfusion of the lumen and the extraluminal space (ECS) with calibrated flows of
culture media and measurement of timed collections of media from each flow. The
bioreactor was tested to see if transport could be increased by creating an oncotic
driving force across the monolayer, and if that increase could be abrogated by oua-








 ATPase, the enzyme responsible for the bulk of
sodium transport across the luminal surface of the cell, which suggested that the
transport was an active process, rather than passive flow governed by Starling forces
across a semipermeable membrane. To increase the oncotic pressure, bovine serum
albumin (BSA) was added to the ECS perfusate, and then ouabain was also added to




 1. As expected, the transport




We further explored the metabolic characteristics of the cultured proximal tubule
cells. We examined the transport of glucose, bicarbonate, and glutathione and
expressed the data in terms of fractional reabsorption accomplished by the bioreac-
tor, now termed the renal tubule assist device, or RAD. For each of the molecules
listed, fractional excretion was measured in the absence and presence of a known
inhibitor of an enzyme essential for the reabsorption. In the case of glucose, the com-
pound phlorizin was used; for bicarbonate, a carbonic anhydrase inhibitor, aceta-
















Adapted from Reference 31.
 










































Adapted from Reference 31.
 
Molecule Condition Fractional Reabsorption (percent)
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acivicin, was used. The data are summarized in TABLE 2. In each case, there was evi-
dence of active transport and specific inhibition.31
The synthesis and secretion of ammonia into the tubule is essential for renal
excretion of an acid load, since it buffers secreted protons. Proximal tubule cells are
able to upregulate their ammoniagenesis in response to a decline in pH, and the prox-
imal tubule cells in the bioreactor demonstrated a stepwise increase in ammonia pro-
duction with changes in pH.31
The experiments detailed above were performed with porcine tubule cells. How-
ever, our laboratory has demonstrated similar results in culture, attachment, and
activity with human proximal tubule cells from cadaveric organs. The final selection
of cell type for use in a renal tubule device rests, not only on supply and safety of
cells, but also on the ability of xenotransplanted cells to participate in the homeosta-
sis of the host. The bioequivalence of large proteins and signalling molecules from
pigs and humans is not well established in the literature to date. Our laboratory
undertook a series of experiments to explore this issue. Human monocytes were iso-
lated from healthy controls by standard methods.33 Human and porcine TNF-α were
used to stimulate monocyte production of IL-8 in vitro. Similarly, porcine IL-10 was
used to attenuate monocyte secretion of TNF-α and IL-8 response to lipopoly-
saccharide stimulation. The results of our experiments are summarized in TABLE 3.34
This demonstration of response of human monocytes to porcine-derived cyto-
kines is encouraging for xenotransplantation research. Of special interest is the find-
ing that porcine IL-10 seems to be able to blunt inflammatory cytokine release from
human monocytes.
The field of xenotransplantation, we must note, although a promising area of
research, is challenged by much more than the aforementioned issue of bioequiva-
lence of signals between organ and host. Detailed understandings of interactions
between MHC-incompatible organs, the immune cells they harbor, and the host, as
well as of zoonotic transmission in both directions are necessary before xenotrans-
plantation research can move from laboratory to clinic.35,36
The above data suggest that our laboratory has successfully isolated and cultured
renal proximal tubule cells, established stable confluent monolayers within hollow
fiber bioreactors, and scaled the initial construct to a level approximating the number
of proximal tubule cells in a single kidney. We termed the large-scale bioreactor the
renal assist device, or RAD.
EX VIVO AND PRECLINICAL CHARACTERIZATION 
OF THE RENAL ASSIST DEVICE
Experimental Model
Following the demonstration of in vitro metabolic activity, we sought to deter-
mine if the metabolic and transport functions we observed in the RAD could be
observed in an ex vivo system. Nephrectomized uremic mongrel dogs were placed
on a modified continuous venovenous hemofiltration (CVVH) circuit. In an analogue
to the glomerular/tubule relationship seen in the kidney, ultrafiltrate from a conven-
tional hollow-fiber dialyzer (Fresenius AG Bad Hamburg, Germany, Model F-40)
was directed to the luminal space of the RAD, and a portion of the posthemofilter
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blood was directed to the extracapillary space of the RAD. Roller pumps were used
to dictate the flow rates of blood and ultrafiltrate to the RAD, as illustrated in
FIGURE 1. The proximal tubule is responsible for reabsorption of approximately 50%
of gloneulus ultrafiltrate, and adjustment of the flow rates and pressures in the RAD
allowed us to mimic that reabsorption rate in our extracorporeal perfusion circuit.
A series of experiments with RADs seeded with proximal tubules and equivalent
hollow-fiber cartridges without cells were conducted. To quantify cell viability, cell
counts were performed on the urine leaving the RAD hourly during the RAD treat-
ment. After removal from the circuit at the conclusion of the experiment, RAD car-
tridges were assessed for cell viability and confluence immediately and after return
to in vitro perfusion with culture media. We examined the ultrafiltrate entering (tubu-
lar fluid) and leaving (urine) the RAD for evidence of vectorial transport and secre-
tion by the cells. Plasma levels of electrolytes, Vitamin D3, and glutathione were
measured before nephrectomy, before RAD treatment, and after RAD treatment.
Cell Viability and Confluence
Urine cell counts obtained during the treatment revealed low levels of detachment
during the first hour of treatment, and little or no detachment thereafter.37 Histologic
sections revealed persistence of the monolayer. Inulin leak rates increased from
5.8% ± 0.9% before the experiment to 10.0% ± 0.9% after the experiment, but after
FIGURE 1. Extracorporeal hemoperfusion circuit.
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14 days of culture had improved to 6.1% ± 0.6%, suggesting that the cells were able
to replicate and reline the interior of the lumen.
Transport Functions of the RAD
We chose to measure the homeostatic properties of the RAD not only by assess-
ing serum concentrations of biologically important compounds, but also by quanti-
fying vectorial transport from the ultrafiltrate to the bloodstream. The ratio of
concentrations between tubular fluid leaving the RAD and ultrafiltrate entering the
RAD (TF/UF) is a convenient expression of vectorial transport, as it quantifies
extraction of a compound from the ultrafiltrate stream. Sodium and water are trans-
ported isoosmotically by the proximal tubule in the kidney and in the RAD. TF/UF
ratios for sodium were approximately 1.00 in our circuit, as expected.37 Fractional
excretion of sodium did reflect active transport across the RAD, which was measured
at 66.5% ± 2.0% in RADs with tubule cells and 52.5% ± 1.4% in sham-treated
controls.37 TF/UF ratios were calculated for the sodium, potassium, chloride, bicar-
bonate, BUN, creatinine, glucose, and glutathione, and are shown in TABLE 4.37
We assessed two other measures of tubule cell metabolism: ammoniagenesis and
serum 1–25 dihydroxy-Vitamin D3 levels in RAD-treated and sham-treated animals.
Total ammonia excretion was assessed by collection of tubular fluid from the RAD.
Excretion of ammonia was measured at –1.38 ± 1.2 µmol/h in sham-treated animals,
and at 41 ± 19.9 µmol/h, (p < 0.02) in treated animals, with peak levels exceeding
90 µmol/h in animals treated for 20–24 hours.37
Serum 1–25 dihydroxy-Vitamin D3 levels in animals treated with the RAD were
also significantly different from levels in sham-treated controls, with levels decreas-
ing by 4.0 pmol/ml over the course of a sham treatment, compared with an increase
of 5.8 pmol/ml in RAD-treated animals.37
We have evidence that cell therapy with proximal tubule cells in our RAD bio-
reactor, in both in vitro and ex vivo models can reproduce many of the key functions
of the renal proximal tubule. Furthermore, in large mammal models, we have
demonstrated significant endocrinologic and metabolic activity reflected in serum
TABLE 4. Tubular fluid/ultrafiltrate ratios (TF/UF)a
aAdapted from Reference 37.
Molecule Sham Treated RAD Treated p
sodium 1.01 ± 0.01 1.00 ± 0.01 NS
potassium 1.00 ± 0.02 0.94 ± 0.02 p < 0.001
chloride 1.01 ± 0.01 1.00 ± 0.01 NS
bicarbonate 0.98 ± 0.01 0.96 ± 0.01 p < 0.05
BUN 1.00 ± 0.01 0.99 ± 0.01 NS
creatinine 1.00 ± 0.01 0.99 ± 0.01 NS
glucose 0.98 ± 0.01 0.88 ± 0.04 p < 0.01
glutathione 0.99 ± 0.07 0.52 ± 0.06 p < 0.001
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chemistries of the treated animal. We then directed our attention to answering one of
the initial questions posed: can functioning proximal tubule cells protect against the
increased mortality seen when acute renal failure complicates other illness?
Role of the RAD in Animal Models in Sepsis
Charles Natanson and others at the National Institutes of Health have developed
and refined a large animal model of septic shock, using lipopolysaccharide infusions
to trigger the proinflammatory cascade that characterizes the sepsis syndrome.38 We
adapted that model to healthy and to bilaterally nephrectomized mongrel dogs to
simulate acute renal failure. Of note, even healthy dogs subject to the stress of
lipopolysaccharide infusions displayed evidence of oliguric renal failure. Prelimi-
nary data suggest that some of the clinical markers of septic shock, such as hypoten-
sion, as well as serum levels of cytokines, such as IL-10, are different between dogs
treated with the RAD and treated with sham controls. Further exploration is under-
way in defining our model.
CLINICAL TRIALS OF THE RAD
The accumulation of several years’ experience with the RAD in large animal
models, as well as the encouraging data from our models of septic shock have
brought us to clinical trials in human patients. The FDA has given approval to pro-
ceed to a PhaseI/II clinical trial of the RAD containing human rather than porcine
cells. We plan to enroll ten patients during the first half of 2001. Our inclusion cri-
teria are designed to enroll patients with acute tubular necrosis already receiving
continuous renal replacement therapy, with APACHE-III predicted mortalities
between 50% and 90%. We eagerly look forward to ushering in a new era of treat-
ment for patients with acute and chronic renal failure.
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